# PEMBRO-RT (NCT02492568)

> Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02492568
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: The Netherlands Cancer Institute
- Conditions: Non-Small Cell Lung Cancer
- Interventions: pembrolizumab; Stereotactic Body Radiation Therapy
- Enrollment: 92
- Primary outcome: Overall Response Rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pembro-rt-nct02492568